During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|May 18, 2017
Long-Term Strategies in Advanced HCC
Long-Term Strategies in Advanced HCC
Advertisement
May 2016
- A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively
April 2017
- Documented radiographic progression
- Therapy with regorafenib at 160mg was initiated
- Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
4
How Patient Factors Steer Treatment Selection in Metastatic Melanoma
5